News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medicis (MRX) Announces FDA Approval of PMA Supplement for RESTYLANE



10/10/2008 7:43:30 AM

SCOTTSDALE, Ariz., Oct. 10, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX - News) today announced the U.S. Food and Drug Administration (FDA) has approved its premarket approval application (PMA) supplement, based on clinical data which highlights RESTYLANE(R)'s duration effect up to 18 months in 97% of patients with repeated treatment. The RESTYLANE(R) package insert will be amended to include the study results. The Company anticipates using this information in its promotional activities.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES